Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer.

Onco Targets Ther · 2018 · PMC5907894 · PMID 29713183

Europe PMC DOI

hedged sentence

0.0969

closest p · 1.9× alpha

0.0969

boldest claim

The sentences

showed a trendP =0.0969so close (0.05 < p ≤ 0.1)

Patients with the exon 19 deletion showed a trend toward a longer median OS (not reached) than that of patients with the exon 21 L858R mutation (23.2 months; 95% CI, 0.22–1.13; P =0.0969) in Figure 2A .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.